Similar articles for PMID: 30842173

Year	Number of Results
1889	1
1996	1
1997	1
2000	2
2003	2
2004	1
2007	5
2008	1
2009	3
2010	4
2011	10
2012	7
2013	6
2014	6
2015	9
2016	13
2017	12
2018	7
2019	11
2020	7
2021	12
2022	10
2023	9
2024	8
2025	1

1

Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer.

Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Anticancer Res. 2019 Mar;39(3):1391-1396. doi: 10.21873/anticanres.13253. Anticancer Res. 2019. PMID: 30842173

2

Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer.

Kobayashi T, Namitome R, Hirata YU, Shiota M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M. Kobayashi T, et al. Anticancer Res. 2019 Jun;39(6):3191-3195. doi: 10.21873/anticanres.13457. Anticancer Res. 2019. PMID: 31177166

3

Novel Treatment Strategies for Low-Risk Metastatic Castration-Sensitive Prostate Cancer.

Iwamoto H, Hori T, Nakagawa R, Kano H, Makino T, Naito R, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Mizokami A. Iwamoto H, et al. Cancers (Basel). 2024 Sep 19;16(18):3198. doi: 10.3390/cancers16183198. Cancers (Basel). 2024. PMID: 39335169 Free PMC article.

4

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.

Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, Latorzeff I, Delva R, Krakowski I, Laguerre B, Walz J, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Oudard S. Gravis G, et al. Eur Urol. 2015 Aug;68(2):196-204. doi: 10.1016/j.eururo.2014.09.022. Epub 2014 Sep 30. Eur Urol. 2015. PMID: 25277272 Clinical Trial.

5

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K. Kijima T, et al. BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28. BJU Int. 2012. PMID: 22369348

6

A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.

Lv W, Shang H, Pei X, Chen Y, Xie H, He D, Wang X, Li L. Lv W, et al. Int Urol Nephrol. 2017 Jan;49(1):61-67. doi: 10.1007/s11255-016-1456-z. Epub 2016 Nov 11. Int Urol Nephrol. 2017. PMID: 27837416

7

Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer.

Mitsui Y, Yamabe F, Hori S, Uetani M, Aoki H, Sakurabayashi K, Okawa M, Kobayashi H, Nagao K, Nakajima K. Mitsui Y, et al. Front Oncol. 2023 Jun 2;13:1162820. doi: 10.3389/fonc.2023.1162820. eCollection 2023. Front Oncol. 2023. PMID: 37333829 Free PMC article.

8

Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer.

Tsuzuki S, Kawano S, Fukuokaya W, Mori K, Nishikawa H, Tashiro K, Watanabe D, Uchimoto T, Nishimura K, Yano Y, Murakami M, Koike Y, Hata K, Koide H, Miki J, Abe H, Yamada H, Naruoka T, Sugaya S, Kimura T, Tomita M, Nakajo H, Egawa S. Tsuzuki S, et al. Jpn J Clin Oncol. 2021 Nov 1;51(11):1665-1671. doi: 10.1093/jjco/hyab115. Jpn J Clin Oncol. 2021. PMID: 34296282

9

Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.

Park YH, Hwang IS, Jeong CW, Kim HH, Lee SE, Kwak C. Park YH, et al. J Urol. 2009 Jun;181(6):2520-4; discussion 2525. doi: 10.1016/j.juro.2009.01.104. Epub 2009 Apr 16. J Urol. 2009. PMID: 19371894

10

Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer.

Roy S, Sun Y, Wallis CJD, Morgan SC, Grimes S, Malone J, Kishan AU, Mukherjee D, Spratt DE, Saad F, Malone S. Roy S, et al. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):119-125. doi: 10.1038/s41391-022-00560-3. Epub 2022 Jul 5. Prostate Cancer Prostatic Dis. 2023. PMID: 35790787 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

120 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 30842173

120 results

Results by year